CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
CeriBell got approval to charge Medicare an extra $2,171 per patient for using its special brain-monitoring device. This means hospitals can now afford to buy and use the company's tool more easily, which could help CeriBell sell more of them.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.